MFN PRICE™ · Pricing exposure framework
Most Favored Nation pricing is not one price. It is cross-market transmission.
01
Exposure becomes urgent when strategic flexibility is limited.
02
Two assets with the same exposure can call for opposite decisions.
03
The launch sequence is usually decided once, on regulatory and affiliate timing, and rarely revisited. Under MFN it is often the single most expensive line in the plan.
Four exposure dimensions
Exposure is scored on four dimensions, then read against the strategic flexibility that remains: timing, contracting, evidence, indication sequencing and portfolio options.
Likelihood and degree of MFN applicability to the asset and its channels.
Vulnerability to a low international benchmark, and which market sets it.
How strongly a price change in one market propagates across the others.
Financial consequence for the product and the company if the pressure materialises.
Exposure alone never sets the management priority. The pair does.
Two assets can carry identical exposure and require opposite decisions depending on how much room is left to act. The two scores are produced separately and read together.
The decision path
Management outputs
Where each asset sits on exposure against flexibility, and which ones need a decision this quarter.
Which market sets the reference price, and what moving or holding it is worth.
The levers that remain: timing, contracting, evidence and portfolio, each with its owner.
Exposure and flexibility scored separately, one management priority, and a market-by-market view of what each action is worth. Senior-led throughout.
Book a demoOr leave details and the team will reach out within one business day.
Frequently asked
In practice it means the US price is referenced against prices in a basket of other high-income countries. A price agreed in one reference market can therefore reshape the economics of the US market. The mechanism turns each international launch and price decision into a cross-market decision.
The lowest net price in the basket sets the reference, so the answer depends on the product's launch sequence and the markets included. For many assets it is a mid-sized European market with a low negotiated price. MFN PRICE identifies which market sets the reference for a given product.
It can, where that market would otherwise set the reference and where delay does not forfeit more value than it protects. The trade-off is product-specific: patient volume, timing, contracting options and the remaining basket all change the result. MFN PRICE simulates what delaying, dropping or resequencing each market is worth.
International reference pricing has long shaped ex-US prices. MFN extends the referencing into the US market, usually the largest single source of revenue, so the financial consequence of a low reference price is far greater. Exposure is therefore a question of scale and transmission, not only of comparison.
Timing of later launches, contracting structures, the evidence that supports the price in each market, indication sequencing and portfolio decisions all remain in play. MFN PRICE scores this strategic flexibility separately from exposure, because two assets with the same exposure can require opposite decisions depending on how much room remains.